TEDx Talks · Published 2023-05-25

Accelerating Clinical Trials with AI: The Future of AI and Health | Michael Lingzhi Li | TEDxBoston

Open on YouTube ↗

Summary

Overview

  • Speaker: Michael Lingzhi Li
  • Channel: TEDx Talks
  • Main topic: How artificial intelligence accelerates and improves clinical trials in medicine
  • Purpose: To demonstrate how artificial intelligence can fundamentally revolutionize drug development and clinical trial execution by improving location selection, recruitment, monitoring, and analysis. Michael Lingzhi Li, assistant professor at Harvard Business School, discusses how traditional clinical trials are expensive, lengthy, and low-success. He introduces DELPHI, an AI-driven tool used during the COVID-19 pandemic to optimize trial locations for Janssen's COVID-19 vaccine trial, demonstrating how AI can accelerate trials, reduce participant burden, and improve trial diversity and efficacy insights.

Topic Map

Modern Clinical Trials Overview

  • Explanation: Explaining the four-step traditional clinical trial process: location selection, recruitment, monitoring, and analysis.
  • Key claims:
    • Clinical trials are the gold standard for determining if a drug works
    • Average cost is greater than $1.2B per trial
    • Process takes over 5 years with a success rate under 20%
  • Examples:
    • Four-step trial process: Location Selection -> Recruitment -> Monitoring -> Analysis
  • Terminology:
    • clinical trials
    • phase III clinical trial
  • Why it matters: Highlights why modern drug development is becoming increasingly difficult and expensive.

The First Successful AI-Driven Phase III Clinical Trial

  • Explanation: Examining the collaboration between MIT and Janssen during COVID-19 to use AI for optimizing a vaccine trial.
  • Key claims:
    • AI tool named DELPHI generated alternate timelines and predicted high-COVID locations 4 months in advance
    • Successfully accelerated trial selection and execution
  • Examples:
    • Janssen COVID-19 Vaccine trial trial site selection across 8 countries
  • Terminology:
    • DELPHI
    • phase III vaccine trial
  • Why it matters: Proves that AI can successfully guide real-world critical healthcare decisions under extreme time pressure.

Impact of AI-Accelerated Trials

  • Explanation: Quantifying the benefits achieved by using AI-driven trial site selection in the Janssen vaccine trial.
  • Key claims:
    • Accelerated trial by 8 weeks (33% reduction in trial length)
    • Needed 15,000 fewer participants (25% reduction)
    • Achieved the most diverse COVID-19 vaccine trial and first with variant efficacy data
  • Examples:
    • Trial sites in Brazil and South Africa providing data on beta and gamma variants
  • Terminology:
    • efficacy data
    • variant efficacy
    • diverse trial
  • Why it matters: Demonstrates tangible real-world benefits in time, cost, participant burden, and demographic representation.

The Future of AI in Clinical Trials

  • Explanation: Outlining how AI will transform all stages of clinical trials moving forward.
  • Key claims:
    • AI can make trials accessible to underrepresented groups
    • AI enables remote monitoring without clinic visits or invasive tests
    • AI personalizes treatments to individual physiology
  • Examples:
    • Remote patient monitoring and decentralized trial structures
  • Terminology:
    • personalized treatment
    • remote monitoring
    • decentralized trials
  • Why it matters: Shifts the paradigm of drug testing from generalized populations to personalized, accessible healthcare.

Key Points

Traditional clinical trials are bottlenecks in drug development

  • Explanation: Taking over 5 years, costing over $1.2 billion, and having a success rate under 20%, clinical trials represent a major barrier to medical innovation.
  • Evidence: >$1.2B average cost, >5 years duration, <20% success rate.
  • Practical implication: New drugs are becoming harder and more expensive to produce without technological intervention.

AI solves the location prediction challenge

  • Explanation: By predicting disease hotspots months in advance, AI enables trial planners to select locations with high patient incidence, shortening trial periods.
  • Evidence: Janssen vaccine trial accelerated by 8 weeks using DELPHI tool.
  • Practical implication: Reduces time-to-market for life-saving therapeutics during pandemics or major health crises.

AI improves trial diversity and data quality

  • Explanation: Expanding trial locations to regions not previously considered naturally increases participant diversity and captures variant-specific efficacy data.
  • Evidence: Inclusion of Brazil and South Africa yielded variant efficacy data for beta and gamma strains.
  • Practical implication: Treatments become safer and more effective across diverse global populations.

Frameworks, Models & Processes

Four-Step Clinical Trial Process

  • How it works: Standard sequential pipeline used to test new drugs and vaccines in human populations.
  • Components:
    • Location Selection
    • Recruitment
    • Monitoring
    • Analysis
  • When to use: Standard pharmaceutical drug development and validation.

Examples & Case Studies

MIT and Janssen used the AI tool DELPHI to select trial locations for the COVID-19 vaccine trial in May 2020.

  • Illustrates: How AI-driven trial site selection speeds up clinical trials and enhances diversity.
  • Lesson: AI can successfully forecast epidemiological trends months in advance to optimize trial outcomes.

Actionable Takeaways

  • Immediate:
    • AI can cut clinical trial duration by over 30%
    • AI-driven selection reduces the required number of trial participants significantly
  • Strategic:
    • AI opens up trial participation to historically underrepresented groups
    • Personalized medicine and remote monitoring are the next frontiers for clinical AI
  • Questions to investigate:
    • How can regulatory bodies ensure trust in AI-driven trial site selection?
    • What privacy safeguards are required for remote patient monitoring in AI clinical trials?

Claims Worth Verifying

  • Traditional clinical trials cost over $1.2 billion on average. (statistical)
  • DELPHI tool accelerated the Janssen COVID-19 vaccine trial by 8 weeks. (empirical)

Notable Quotes

"Today I'm going to tell you how AI is going to fundamentally change how we test new drugs." (at 0:15) "We managed to accelerate the trial by 8 weeks using these AI selected trial locations." (at 5:49)

Compressed Summary

  • Traditional clinical trials are slow, costly, and have low success rates.
  • AI tool DELPHI successfully optimized trial locations for the Janssen COVID-19 vaccine.
  • AI accelerated the trial by 8 weeks and reduced participant needs by 25%.
  • AI-driven trials achieved greater demographic diversity and variant efficacy data.
  • Future applications include remote monitoring and personalized medicine.
  • Keywords: artificial intelligence, clinical trials, vaccine development, delphi, healthcare innovation
  • Core insight: Artificial intelligence transforms clinical trials by predicting optimal trial locations, accelerating timelines, reducing participant burdens, and improving demographic diversity.

Core insights

6
Mechanismhigh noveltymoderate evidence

The AI tool DELPHI was used to generate alternate timelines and forecast high-incidence locations four months before trial site commitment, i.e., counterfactual simulation of a plan space plus environment forecasting, executed before any irreversible spend.

Why it matters

Planning under uncertainty is usually done by cheap heuristics; here a model enumerated alternative futures to choose among mutually exclusive, expensive, hard-to-reverse commitments. This is a reusable pattern for any system where an initial placement decision gates all downstream cost.

Generalization

Before committing to an expensive, hard-to-reverse resource placement, run model-generated counterfactual scenarios and pick the option that stays good across a distribution of predicted futures rather than the best case in the current state.

AI tool named DELPHI generated alternate timelines and predicted high-COVID locations 4 months in advance
Open source video
By predicting disease hotspots months in advance, AI enables trial planners to select locations with high patient incidence, shortening trial periods.
Open source video
Mental Modelmedium noveltystrong evidence

The single upstream decision of where to run the trial (site selection) produced the majority of downstream gains: 33% shorter trial, 25% fewer participants, plus diversity and variant data. One early configuration choice dominated the entire pipeline's outcomes.

Why it matters

Effort spent optimizing late-stage steps can be worthless if an upstream placement/configuration decision already determined the ceiling. Engineering effort should be allocated by leverage, not by where the pain is most visible.

Generalization

Locate the earliest decision that constrains everything downstream and instrument/optimize there first; downstream tuning cannot recover a bad upstream placement.

We managed to accelerate the trial by 8 weeks using these AI selected trial locations.
Open source video
Accelerated trial by 8 weeks (33% reduction in trial length)
Open source video
Needed 15,000 fewer participants (25% reduction)
Open source video
Empirical Resulthigh noveltymoderate evidence

Diversity of participants and the first variant-efficacy data were obtained as a byproduct of optimizing site selection for incidence, not as an explicit objective: coverage came from where data was collected, not from a coverage-aware objective.

Why it matters

Suggests evaluation coverage is a property of the collection topology (where you sample) rather than a property of a sampling policy applied after the fact. Relying on incidental coverage is fragile; making it a byproduct of a different objective means it can vanish when that objective changes.

Generalization

Edge-case and distribution coverage in any evaluation harness derives from the topology of data collection; if coverage is not an explicit term in the placement objective, treat it as luck, not a guarantee.

Achieved the most diverse COVID-19 vaccine trial and first with variant efficacy data
Open source video
Trial sites in Brazil and South Africa providing data on beta and gamma variants
Open source video
Mental Modelmedium noveltystrong evidence

The target regime is high-cost, low-repetition, low-base-rate: over $1.2B and over 5 years per trial with under 20% success, meaning very few expensive runs and almost no cheap iteration loop.

Why it matters

When runs are extremely scarce and expensive, offline simulation, forecasting, and prediction are disproportionately valuable relative to try-observe-adjust loops. It is the inverse of the assumption behind most agent engineering practice, which assumes cheap, frequent runs.

Generalization

Systems with expensive, low-count executions need stronger pre-execution modeling and simulation than systems with cheap, high-count executions; tooling priorities invert.

Average cost is greater than $1.2B per trial
Open source video
Process takes over 5 years with a success rate under 20%
Open source video
Predictionmedium noveltyweak evidence

The proposed future direction moves measurement out of the execution site: remote monitoring without clinic visits or invasive tests, i.e., continuous in-situ telemetry replacing episodic centralized checkpoints.

Why it matters

Decoupling observation from the execution venue changes what can be measured, how often, and who holds the data, creating a new privacy/security boundary in the architecture.

Generalization

Shift from episodic centralized measurement to continuous remote telemetry changes the observability layer's ownership, sampling rate, and trust boundary simultaneously.

AI enables remote monitoring without clinic visits or invasive tests
Open source video
Remote patient monitoring and decentralized trial structures
Open source video
Predictionmedium noveltyweak evidence

Personalization is framed as tailoring treatment to individual physiology, moving from a single population-level protocol to per-instance configuration.

Why it matters

Per-instance adaptation changes the evaluation problem: a global metric can no longer validate a policy that deliberately behaves differently per instance, so per-instance or stratified evaluation becomes necessary.

Generalization

Once a system adapts per instance, aggregate metrics stop being sufficient evidence of correctness; evaluation must become stratified by the same variables the policy conditions on.

AI personalizes treatments to individual physiology
Open source video

Deep dives

5

Forecast-gated pipelines: propagation of forecast error into irreversible commitments

Research question

When a model forecast becomes the blocking gate in front of an expensive, hard-to-reverse commitment, how should forecast error be measured, versioned, and bounded so that a wrong forecast degrades gracefully instead of poisoning the whole downstream pipeline?

Why

The summary describes DELPHI predicting hotspots four months ahead and gating site selection, but reports no forecast-accuracy metric, error distribution, or fallback. If the gate is wrong, every downstream cost and endpoint is affected, so the forecast itself needs its own validation and fallback architecture.

AI tool named DELPHI generated alternate timelines and predicted high-COVID locations 4 months in advance
Open source video
By predicting disease hotspots months in advance, AI enables trial planners to select locations with high patient incidence, shortening trial periods.
Open source video
Source video

Upstream-decision leverage: measuring where the pipeline's ceiling is set

Research question

How can we empirically attribute downstream gains (33% shorter, 25% fewer participants) to a single upstream placement decision rather than to post-hoc attribution, and what counterfactual construction makes that attribution falsifiable?

Why

The claim that site selection dominated all downstream outcomes is the strongest insight in pass 1, but the 8-week acceleration may be a counterfactual estimate or a post-hoc attribution. If leverage is misattributed, engineering effort is spent on visible pain rather than on the constraining decision.

We managed to accelerate the trial by 8 weeks using these AI selected trial locations.
Open source video
Accelerated trial by 8 weeks (33% reduction in trial length)
Open source video
Needed 15,000 fewer participants (25% reduction)
Open source video
Source video

Coverage as a byproduct vs. coverage as a constraint in placement objectives

Research question

Is distributional coverage in evaluation or trial populations reproducible when it is an incidental byproduct of optimizing for a different objective, or does it require an explicit coverage term in the placement objective?

Why

Diversity and first variant-efficacy data appeared as observed results, not stated goals. If coverage is inherited luck from the placement topology, it silently vanishes whenever the optimization objective changes, which is a hidden fragility in any sampling or evaluation design.

Achieved the most diverse COVID-19 vaccine trial and first with variant efficacy data
Open source video
Trial sites in Brazil and South Africa providing data on beta and gamma variants
Open source video
Source video

Evaluation under scarce, expensive, low-repetition runs

Research question

What evaluation harness, surrogate endpoints, or simulation substitutes are valid when the real execution is a single $1.2B, 5-year event with under 20% success, and how do we detect when a surrogate has decoupled from the real outcome?

Why

Most agent engineering assumes cheap, frequent runs; the inverse regime inverts tooling priorities toward offline modeling. Evaluation design for low-repetition, high-cost runs is the least-addressed problem in the pass-1 analysis.

Average cost is greater than $1.2B per trial
Open source video
Process takes over 5 years with a success rate under 20%
Open source video
Source video

Auditability of model-chosen placements under regulatory review

Research question

What audit-trail structure (candidate set, forecasts, rejected alternatives, objective terms) is sufficient for an external authority to review a model-chosen placement decision rather than merely accept its output?

Why

The summary raises trust in AI-driven site selection as an unresolved question. An executable decision that is not reviewable cannot be trusted in a high-stakes pipeline, so reviewability becomes an architectural requirement, not a documentation nicety.

How can regulatory bodies ensure trust in AI-driven trial site selection?
Open source video
How can regulatory bodies ensure trust in AI-driven trial site selection?
Open source video
Source video

Article ideas

4

The Ceiling Is Set Upstream: Why Optimizing Late-Stage Steps Cannot Recover a Bad Placement Decision

In pipelines with rare, expensive, hard-to-reverse executions, the earliest placement or configuration decision determines the ceiling on every downstream metric, so engineering effort allocated by visible pain is systematically misallocated; effort should be allocated by leverage, and leverage must be demonstrated with a counterfactual rather than asserted post-hoc.

Angle

Use the trial-site case (one placement choice producing 33% shorter duration and 25% fewer participants) as the worked example, then transpose the same leverage structure to abstraction boundaries and resource placement in software systems, insisting throughout that attribution be made falsifiable.

Source video

Coverage You Didn't Ask For Is Coverage You Don't Have

Distributional coverage in any evaluation or sampling regime is a property of the collection topology, not of a post-hoc sampling policy; when coverage is an incidental byproduct of a different optimization objective, it must be treated as luck rather than a guarantee, because changing the objective silently changes the coverage.

Angle

Contrast the observed diversity and variant-efficacy outcome of the AI-selected sites against what a coverage-aware placement objective would have required, and argue for promoting coverage to a first-class constraint in placement objectives and evaluation harnesses alike.

Source video

Forecast-as-Gate: The Systemic Risk of Blocking Dependencies Built on Predictions

When a predictive model becomes a blocking dependency at the front of an expensive pipeline, forecast error stops being a model metric and becomes a systemic risk that propagates through everything downstream; such gates therefore require their own validation, versioning, error bounds, and explicit fallback path before they are allowed to gate anything irreversible.

Angle

Frame the four-month-ahead location forecast as a gating dependency whose accuracy was never reported in the source, then derive the minimum engineering obligations for any forecast that sits in front of an irreversible commitment.

Source video

How Do You Evaluate a Run You Can Only Afford Once?

The standard agent and software evaluation playbook assumes cheap, repeatable runs, and it inverts in regimes of scarce, expensive, low-base-rate executions; there, simulation, surrogate endpoints, and offline counterfactual modeling are not nice-to-haves but the only available evidence, which means surrogate validity itself becomes the central research problem.

Angle

Use the $1.2B, 5-year, sub-20%-success trial regime as the extreme case, and argue that teams building high-stakes autonomous systems should be investing in offline simulation harnesses and surrogate-validity checks rather than in more repetitions of an unaffordable run.

Source video

Project ideas

4

ForecastGate Backtester

beyond-evals

A prospective placement/forecast gate can be scored before deployment, and its realized forecast error is predictive of downstream pipeline cost, such that error-aware gating (choose the option robust across the predicted distribution) outperforms point-forecast gating on downstream cost and time.

Proof of concept

Build a harness that replays historical incidence time series, produces four-month-ahead candidate-location forecasts with a point model and an ensemble/distribution model, selects placements under each policy, and computes downstream cost (time-to-endpoint accumulation, participant count) under realized incidence; include a deliberate forecast-failure regime and a fallback policy.

Measurement

Forecast precision/recall at four months versus baseline; downstream time-to-endpoint and participant count for point-gate vs distribution-gate vs no-gate; degradation curve of downstream cost as a function of induced forecast error.

Source video

Coverage-Ablation Placement Study

beyond-evals

Population/strain coverage of a placement-optimized sampling plan is not reproducible by chance; adding an explicit coverage term to the placement objective produces significantly more reliable coverage than incidence-only optimization, and incidence-only plans lose coverage silently when the incidence objective or forecast changes.

Proof of concept

Construct a synthetic or historical candidate-site pool with demographic and variant metadata, run placement optimization under three objectives (incidence-only, coverage-only, incidence+coverage), perturb the forecast and the objective, and compare resulting covered subpopulations across perturbations.

Measurement

Coverage of target subpopulations per plan; variance of coverage across forecast perturbations; rate at which incidence-only coverage collapses when the objective changes.

Source video

Decision Audit Trail for Model-Chosen Placements

gatehouse

A structured, reviewable audit record (candidate set, per-candidate forecasts, objective terms and weights, rejected alternatives, and the selected option with rationale) materially increases an external reviewer's ability to accept or reject a model-chosen placement decision compared with exposing only the final selection.

Proof of concept

Prototype a decision-record schema and generator around a placement optimizer; run a small review study in which reviewers judge placement decisions with and without the full record, and measure acceptance consistency and time-to-decision.

Measurement

Inter-reviewer agreement on accept/reject; time to reach a decision; number of reviewer questions that the record already answers; rate of decisions reversed when the record is revealed after a bare selection.

Source video

Low-Repetition Eval Harness with Surrogate-Validity Monitor

beyond-evals

In a regime where the real run can be afforded only once, a surrogate-endpoint harness with an explicit surrogate-validity monitor (tracking drift between surrogate signals and any available ground-truth anchor) detects surrogate decoupling earlier than a harness that reports surrogate scores alone.

Proof of concept

Build an offline evaluation harness where the expensive ground-truth run is simulated, surrogates are cheap proxies, and the harness continuously estimates surrogate-to-truth correlation; inject regime shifts that break the surrogate and measure detection latency against a surrogate-only baseline.

Measurement

Detection latency of surrogate decoupling; false-alarm rate; variance of the final go/no-go recommendation under repeated simulated regimes with and without the validity monitor.

Source video

Architectural implications

3

A forecasting model (DELPHI) sits upstream of an expensive execution pipeline and gates it.

Before

Site/location selection was a planning step made without a forward-looking model of future conditions.

After

A predictive model becomes a blocking dependency at the front of the pipeline, and its forecasts determine the shape of everything downstream.

Consequence

Forecast error becomes a systemic risk that propagates through the whole pipeline; the model needs its own validation, versioning, and fallback path.

Source video

Optimization objective was narrowed to predicted incidence at candidate sites, with representativeness not appearing as an explicit term.

Before

Diversity of the trial population was presumably an aspiration handled independently of site selection.

After

Coverage properties are inherited from the placement decision, making placement the de facto diversity mechanism.

Consequence

Any change to the placement objective silently changes coverage; coverage should be promoted to a first-class constraint in the objective rather than an observed outcome.

Source video

Measurement moves from clinic visits to remote monitoring.

Before

Observation happens at a controlled, trusted venue with institutional privacy controls.

After

Observation happens at the participant's location over a network, with the device and channel becoming part of the trust boundary.

Consequence

The observability layer acquires its own security, consent, and data-retention architecture instead of inheriting the venue's.

Source video

Tradeoffs and failure modes

4

AI as decision authority in high-stakes pipelines

Benefit

AI-driven site selection materially shortened the trial and reduced participant burden.

Cost or risk

Trust and regulatory acceptance are treated as unresolved; a model-chosen decision must be justifiable to external authorities.

How can regulatory bodies ensure trust in AI-driven trial site selection?
Open source video
Source video

Continuous remote monitoring

Benefit

Enables monitoring without clinic visits or invasive tests, lowering participant burden and enabling decentralized trials.

Cost or risk

Introduces privacy and data-handling obligations that the summary explicitly leaves unresolved.

What privacy safeguards are required for remote patient monitoring in AI clinical trials?
Open source video
Source video

Smaller trials via better site selection

Benefit

15,000 fewer participants were needed, reducing cost and burden.

Cost or risk

The summary reports the reduction without describing how statistical power or confidence was preserved; a smaller sample is only safe if the placement change actually raised event capture, which the summary asserts rather than demonstrates.

Needed 15,000 fewer participants (25% reduction)
Open source video
Source video

Narrowing the objective to predicted hotspots

Benefit

Higher-incidence sites shorten the time needed to accumulate endpoints.

Cost or risk

Hotspot optimization is a point forecast under a fast-changing epidemic; the summary presents no measurement of forecast error or of what happens when the prediction is wrong.

AI tool named DELPHI generated alternate timelines and predicted high-COVID locations 4 months in advance
Open source video
Source video

Open questions

4

How accurate was the four-month-ahead location forecast, and how does the pipeline degrade when it is wrong?

Why unresolved

The summary reports the selection benefit but no forecast-accuracy metric, error distribution, or fallback behavior.

Research direction

Build a backtest harness that scores prospective placement forecasts against realized incidence and measures downstream cost of forecast error.

Source video

Was the diversity and variant-efficacy outcome caused by the AI placement strategy or incidental to the set of countries chosen?

Why unresolved

Diversity appears as an observed result, not as a stated objective or a controlled comparison.

Research direction

Re-run placement optimization with and without an explicit coverage term and measure whether population diversity is reproducible or lucky.

Source video

What oversight mechanism makes a model-chosen placement decision acceptable to regulators?

Why unresolved

The summary raises the trust question without proposing an answer.

Research direction

Prototype an audit trail that records candidate sites, forecasts, and rejected alternatives so the decision is reviewable, not just executable.

Source video

What does an evaluation harness look like when the execution run is a single $1.2B, 5-year, sub-20%-success event?

Why unresolved

The summary quantifies the cost/latency/success regime but does not describe surrogate or simulated evaluation methods.

Research direction

Investigate simulation-based and surrogate-endpoint evaluation as substitutes for repeated real runs in low-repetition regimes.

Source video

Key claims

7
factualVerification needed

The average clinical trial costs more than $1.2 billion.

Evidence

Average cost is greater than $1.2B per trial

Question

Does the cited $1.2B figure cover fully loaded capitalized cost including failures, and what is its source?

Source video
factualVerification needed

Clinical trials take over five years with a success rate under 20%.

Evidence

Process takes over 5 years with a success rate under 20%

Question

Is the sub-20% rate measured per phase, per indication, or across all drug programs?

Source video
causalVerification needed

DELPHI predicted high-COVID locations four months in advance and generated alternate timelines.

Evidence

AI tool named DELPHI generated alternate timelines and predicted high-COVID locations 4 months in advance

Question

What was the measured precision/recall of those four-month-ahead location predictions versus a baseline?

Source video
causalVerification needed

Using AI-selected trial locations accelerated the Janssen vaccine trial by 8 weeks.

Evidence

We managed to accelerate the trial by 8 weeks using these AI selected trial locations.

Question

Is the 8-week figure a counterfactual estimate or a post-hoc attribution, and how was the counterfactual constructed?

Source video
causalVerification needed

The AI-selected locations reduced required participants by 15,000 (25%).

Evidence

Needed 15,000 fewer participants (25% reduction)

Question

How was statistical power preserved with 25% fewer participants, and against what baseline was the reduction computed?

Source video
comparativeVerification needed

The trial was the most diverse COVID-19 vaccine trial and the first with variant efficacy data.

Evidence

Achieved the most diverse COVID-19 vaccine trial and first with variant efficacy data

Question

What diversity metric and comparison set support 'most diverse', and is the variant-efficacy claim attributable to site placement?

Source video
predictionVerification needed

AI will personalize treatments to individual physiology.

Evidence

AI personalizes treatments to individual physiology

Question

What evidence exists that per-individual physiological personalization outperforms stratified or population-level protocols?

Source video

Connections

5